Navigation Links
Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
Date:2/9/2011

EAST HANOVER, N.J., Feb. 9, 2011 /PRNewswire/ -- The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)(1).

Data from the study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), were first presented last year at the 12th World Congress on Gastrointestinal Cancer in Barcelona(2). Regulatory submissions for everolimus to treat this patient population are underway worldwide.

Results from the trial showed that everolimus more than doubled median PFS from 4.6 to 11.0 months when compared with placebo and reduced the risk of cancer progression by 65% (hazard ratio [HR] =0.35 [95% confidence interval (CI), 0.27 to 0.45]; p<0.001) in patients with advanced pancreatic NET. After 18 months, 34% of patients treated with everolimus (95% CI, 26 to 43) were alive and progression-free versus 9% of those treated with placebo (95% CI, 4 to 16), showing a more prolonged benefit for patients treated with everolimus(1).

Pancreatic NET originates from the islet cells of the pancreas and can grow aggressively(3). It is a distinct and uncommon disease that is different from what is generally referred to as pancreatic cancer or pancreatic exocrine cancer(4). At time of diagnosis the majority of patients have advanced disease, meaning the cancer has spread to other parts of the body and has become more difficult to treat(3),(5). The median survival duration for patients with advanced pancreatic NET is 24 months(6).

"A patient diagnosed with advanced NET may have limited treatment options," said James Yao, MD, Associate Professor of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. "Results from the RADIANT-3 trial are encouraging and demonstrate the potential
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Prepare your probe in less , ... Ideal for siRNA/miRNA studies , , ... activity RNA probes for RPA, Northern, Southern, or in situ hybridization , ... No cloning required , With ...
... Reagents and , ... Superior identification of target cells provided ... Designed for use , ... Compatible with Arcturus LCM Systems , Use with , ...
... Now it's easy to make your RNA free of genomic DNA , ... , & Removal Reagents contain RNase-free DNase, ... to ensure safe, complete removal of , ... DNase Removal Reagent which, after digestion, eliminates DNase in , ...
Cached Biology Technology:Prepare siRNA and miRNA Probes in Just 1 Hour 2Prepare siRNA and miRNA Probes in Just 1 Hour 3Protect RNA and Improve Target Cell Identification 2Protect RNA and Improve Target Cell Identification 3Protect RNA and Improve Target Cell Identification 4Protect RNA and Improve Target Cell Identification 5Protect RNA and Improve Target Cell Identification 6DNA-free A NEW Method to Remove DNA 2DNA-free A NEW Method to Remove DNA 3DNA-free A NEW Method to Remove DNA 4DNA-free A NEW Method to Remove DNA 5DNA-free A NEW Method to Remove DNA 6DNA-free A NEW Method to Remove DNA 7DNA-free A NEW Method to Remove DNA 8
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... in Europe, Asia and the United States are spreading ... impacting native honeybee populations at this time, according to ... including Nosema microsporidia and Varroa ... to these invasive pests, which suggests to us that ... and the United States currently are not necessary in ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... suggest that policy makers examine greenhouse gas (GHG) ... sources must be rapidly replaced by windmills, solar ... recommendations could be used to help policy makers ... will optimize greenhouse gas emission reductions., "The energy ...
... scientists from Princeton University and The Cancer Institute of New ... the secret lives of cancer cells that go dormant and ... produce new cancer therapies to stem changes that render cancer ... know: What role is this self-cannibalization playing in the middle ...
... aerospace and ocean engineering at Virginia Tech, is the latest ... a National Science Foundation (NSF) Faculty Early Career Development (CAREER) ... 70 Virginia Tech CAREER award winners, of which some 60 ... award was created in 1994. He will receive some $400,000 ...
Cached Biology News:Queen's researchers propose rethinking renewable energy strategy 2Research team targets self-cannibalizing cancer cells 2Research team targets self-cannibalizing cancer cells 3Research team targets self-cannibalizing cancer cells 4Research team targets self-cannibalizing cancer cells 5Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
... double stranded RNA (dsRNA) has been shown ... group of organisms as well as insect ... the inhibition of protein expression by utilizing ... RNA (mRNA). Attempts to induce RNA interference ...
... distinguish collagen from muscle in tissue specimens ... stain is often used to differentiate between ... an increase in collagenous tissue. With the ... red, collagen - blue, fibrin - pink, ...
Biology Products: